Is ARGX a Buy or a Sell? The Bull and Bear Case (2026)

Last updated October 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for argenx SE (ARGX) rests on Vyvgart franchise momentum: Vyvgart posted its 17th consecutive quarter of growth in Q1 2026, with sales near $1.3 billion (up 63% year over year) and roughly 19,000 patients on treatment. The bear case rests on argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. Analysts covering it publish targets from $823.00 to $1356.00 against a $819.14 price, so even the professionals disagree by 46% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

argenx SE is a Netherlands-based, globally operating immunology company that trades in the US as a Nasdaq ADR. Its lead product, Vyvgart and the subcutaneous Vyvgart Hytrulo (efgartigimod), is an FcRn blocker that lowers pathogenic IgG antibodies. It is approved for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), plus primary immune thrombocytopenia in Japan, and reached roughly 19,000 patients on treatment by the end of 2025. The investment picture is a classic biotech growth profile: revenue is compounding quickly (about $4.15 billion in 2025 global product net sales, up roughly 90% year over year, then ~$1.31 billion in Q1 2026 and ~$1.54 billion in Q2 2026, up ~59% year over year), the company is solidly profitable (trailing net income ~$1.72 billion) and holds ~$5.2 billion of cash against minimal debt, and the pipeline aims to expand efgartigimod into new autoimmune indications while advancing next-generation FcRn and complement candidates. Q2 2026 EPS of $7.32 beat a $6.19 consensus, the fourth straight beat. The setback came on October 9, 2026, when argenx stopped its Phase 3 UNITY study of subcutaneous efgartigimod in Sjogren's disease after an independent data monitoring committee found it could not meet its primary endpoint, and the shares fell ~12% that day. In early October Halozyme also expanded its ENHANZE license with argenx to two more exclusive targets. At $817.80 on October 16, 2026, ARGX is down ~2.6% year to date and ~17% over a month, trading at ~31x trailing and ~23x forward earnings with a ~$51.4 billion market cap, so the shares still carry the volatility typical of a single-franchise-led biotech. Third-quarter results are scheduled for October 22, 2026, with consensus revenue near $1.63 billion.

The bull case: what would have to be true for $1356.00

The most optimistic published target on ARGX is $1356.00, +65.5% from the $819.14 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Vyvgart franchise momentum

Vyvgart posted its 17th consecutive quarter of growth in Q1 2026, with sales near $1.3 billion (up 63% year over year) and roughly 19,000 patients on treatment. Uptake of the subcutaneous Hytrulo formulation and continued gMG and CIDP adoption are the core revenue engine. Each new label and geography adds to a still-expanding addressable base. Second-quarter 2026 revenue reached ~$1.54 billion, up ~59% year over year, extending the run.

2. Label and indication expansion

argenx is pursuing efgartigimod in seronegative gMG, ocular myasthenia gravis, primary ITP, Graves' disease and myositis. A widening set of approved uses could turn a single molecule into a multi-indication franchise, but not every expansion will succeed: in October 2026 the Phase 3 UNITY trial in Sjogren's disease was stopped for futility after an interim analysis, removing one of the larger planned indications. Regulatory decisions and Phase 3 readouts in the remaining indications are the near-term swing factors.

3. Deep autoimmune pipeline

Beyond efgartigimod, argenx is advancing next-generation FcRn candidates (such as ARGX-213 and ARGX-124) and first-in-class assets including empasiprubart (a C2 complement inhibitor) and adimanebart. Its Vision 2030 framework targets 10 labeled indications and five pipeline candidates in Phase 3. This breadth is what supports the long-duration growth narrative. In October 2026 argenx added two more exclusive targets to its ENHANZE subcutaneous-delivery license with Halozyme, which earns milestones and royalties on products that use it.

4. Profitability and balance sheet

argenx has crossed into sustained profitability, reporting Q1 2026 profit of about $366 million (up 116% year over year) and Q2 2026 profit of ~$472 million, with adjusted EPS of $5.52 and $7.32 that beat consensus both times. Trailing net income is ~$1.72 billion and cash stood at ~$5.2 billion against ~$47 million of debt at mid-year. That cushion funds pipeline investment without near-term dependence on capital markets.

The bear case: what would have to be true for $823.00

The most pessimistic published target is $823.00, +0.5% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks argenx SE is worth if the risks below bite instead of the drivers above.

argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. The FcRn field is crowding: UCB (rozanolixizumab, zilucoplan), Johnson & Johnson (nipocalimab), and Immunovant (batoclimab and IMVT-1402) are all competing in overlapping indications, and AstraZeneca's complement inhibitors address parts of the same market. Pipeline setbacks can sharply reset expectations given the valuation: the October 2026 futility stop of the Phase 3 UNITY trial in Sjogren's disease sent the shares down ~12% in a day and ~17% over the month. As an ADR of a European company, holders also carry currency and cross-listing considerations. Biotech shares like ARGX tend to be volatile around clinical and regulatory events.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ARGX already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on ARGX

23 analysts cover ARGX, with an average target of $1152.91 (+40.7% against $819.14) and a split of 22 buy, 3 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ARGX forecast and price target page.

How is ARGX valued? (as of October 2026)

Price

$819.14

Market cap

$51.51B

P/E (TTM)

31.22

Forward P/E

23.02

Price / book

152.15

Beta

-0.04

52-week range

$661.85 to $1,072.75

Snapshot for ARGX as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$5.32B; Q2 2026 ~$1.54B, up ~59% year over year
Q2 2026 EPS: $7.32 vs $6.19 consensus; profit ~$472M
Net income (TTM): ~$1.72B; net margin ~32%
P/E: ~31x trailing, ~23x forward
Cash and debt: ~$5.2B cash, ~$47M debt
Market cap: ~$51.4B at $817.80 (Oct 16, 2026)
Dividend: None

At ~31x trailing and ~23x forward earnings, argenx is valued as a profitable growth company rather than a speculative biotech, with consensus expecting revenue of ~$6.3 billion in 2026 and ~$7.76 billion in 2027. The Sjogren's failure trimmed some pipeline value from the price, and the mean analyst target of ~$1,153 across 23 analysts sits well above the $817.80 close. Third-quarter results on October 22, 2026 (consensus revenue ~$1.63 billion) are the next check on Vyvgart growth.

How do you decide if ARGX is a buy?

Rather than asking whether ARGX is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold ARGX indirectly through an index or sector ETF before adding more.

What would change your mind on ARGX

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Vyvgart franchise momentum stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the ARGX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ARGX against your real portfolio and see your actual exposure before deciding.

Investing in argenx SE with AI

Connect the broker you already use and ask Walnut's AI how ARGX fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does ARGX fit me?

FAQ

Is ARGX a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Vyvgart franchise momentum, with revenue (ttm) at ~$5.32B; Q2 2026 ~$1.54B, up ~59% year over year. The bear case rests on argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. Analysts covering it are spread from $823.00 to $1356.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell ARGX?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $823.00, +0.5% from the $819.14 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for ARGX?

Vyvgart franchise momentum. Vyvgart posted its 17th consecutive quarter of growth in Q1 2026, with sales near $1.3 billion (up 63% year over year) and roughly 19,000 patients on treatment. The most optimistic analyst target on ARGX is $1356.00, +65.5% from the $819.14 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for ARGX?

What does argenx SE do?

argenx SE is a Netherlands-based, globally operating immunology company that trades in the US as a Nasdaq ADR.

What would have to change for ARGX to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Vyvgart franchise momentum) stalling in the reported numbers rather than in the narrative, the risk above (argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does argenx do?

argenx is an immunology company focused on autoimmune diseases. Its lead product, Vyvgart (efgartigimod), is an FcRn blocker that lowers harmful IgG antibodies, and it is approved for conditions including generalized myasthenia gravis and CIDP.

What is Vyvgart and why does it matter to ARGX?

Vyvgart, and its subcutaneous version Vyvgart Hytrulo, is efgartigimod, the drug behind nearly all of argenx's revenue. Its adoption in myasthenia gravis and CIDP drove roughly $4.15 billion in 2025 net sales, so Vyvgart uptake is the primary driver of the stock.

Is ARGX profitable?

Yes. argenx reported profit of about $366 million in the first quarter of 2026 and ~$472 million in the second, for trailing net income of ~$1.72 billion, and held roughly $5.2 billion in cash against minimal debt at mid-2026. That is a clear break from the cash-burning profile typical of development-stage biotech.

Walnut is informational, not investment advice, and gives no verdict on ARGX. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.

Guides that feature ARGX

ARGX is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.